- Home
- TDUP vs EIKN Comparison
TDUP vs EIKN Comparison
Compare TDUP & EIKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDUP | EIKN |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 316.3M |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | TDUP | EIKN |
|---|---|---|
| Price | $1.58 | $5.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $2.80 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 1.8M | 535.4K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $310,813,000.00 | N/A |
| Revenue This Year | $11.55 | N/A |
| Revenue Next Year | $10.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.53 | N/A |
| 52 Week Low | $1.24 | $5.01 |
| 52 Week High | $8.76 | $16.50 |
Technical Indicators
Market Signals| Indicator | TDUP | EIKN |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 42.37 |
| Support Level | N/A | $5.01 |
| Resistance Level | $2.52 | $8.48 |
| Average True Range (ATR) | 0.18 | 0.60 |
| MACD | -0.03 | 0.11 |
| Stochastic Oscillator | 30.56 | 51.80 |
Price Performance
Historical ComparisonAbout TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for apparel, shoes, and accessories. The company's marketplaces have enabled buyers in the United States ("U.S.") to browse and purchase resale items principally for apparel, shoes, and accessories across a range of price points. The company's revenue is principally from the sale of secondhand apparel, shoes, and accessories on behalf of sellers.
About EIKN Eikon Therapeutics Inc. Common Stock
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.